Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 2014. The report details a specific share repurchase transaction executed on February 20, 2014, in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share buyback activity.
- Shares Purchased: 59,500 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,687.50 pence per share; lowest price paid was 1,676.00 pence per share.
- Treasury Holdings (Settled): 488,696,169 shares, representing 9.14% of total issued share capital.
- Treasury Holdings (Including Unsettled): 488,755,669 shares, representing 10.06% of total voting rights.
- Shares in Issue (Excluding Treasury): 4,858,097,909 shares.
Material Changes
The filing reports a reduction in outstanding shares due to the purchase of 59,500 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.06% when including unsettled purchases. No other material changes to operations or financial position are disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (488,696,169 settled) against the company's latest annual report.
- Confirm the total issued share capital to validate the 9.14% Treasury ownership calculation.
- Check subsequent filings for the settlement status of the 59,500 shares purchased on February 20, 2014.
- Review the remaining authorization for share buybacks under the mandate granted on May 1, 2013.